title: Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.
abstract: Bendamustine is an agent with mostly alkylating properties, which acts on dividing cells through multiple pathways. As an agent with little cross-resistance with other chemotherapeutic agents, bendamustine has received approval for second-line use in relapsed/refractory indolent lymphomas. A growing body of data showing good efficacy and acceptable tolerability of bendamustine in first-line use has led to recognition that this agent has an important role in this setting. This article outlines the pharmacology and clinical studies supporting the use of bendamustine and discusses the role of this agent in the first- and second-line treatment of indolent lymphomas.
authors.affiliation: University of Ottawa, Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada +1 613 737 8804 +1 613 739 6227 rvanderjagt@toh.on.ca.
authors.forename: Richard
authors.initials: R
authors.lastname: van der Jagt
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D002986:Clinical Trials as Topic; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D009588:Nitrogen Mustard Compounds / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride